Abstract 4259: Long term cell culture models to identify biomarkers of response

In order to test the efficacy of many cancer therapeutics, culturing cells in the presence of compounds for longer than the conventional 72-hr cell growth assay may be necessary. It is shown that the inhibition of many epigenetic targets results in a significantly delayed drug response not revealed by conventional shorter term cell growth assays. OncoPanel™ from Eurofins Pharma Discovery Services is a collection of 300 cell lines with broad cancer type and subtype representation and extensive genomic characterization. We have developed a 10-day assay to test inhibitors of epigenetic targets. Using the EZH2-selective inhibitor, GSK343, we have demonstrated the advantages of cell line profiling under long-term assay conditions when drug response reflects a protracted mechanism of action. We also tested Olaparib, a PARP inhibitor, in this system and showed substancial increased sensitivity against several cell lines versus the 72 hr assay. The significant biomarkers identified from the genomic analysis of the data from both GSK343 and Olaparib substantiate the relevance of long term cell profiling. Citation Format: Usha Warrior, Jonathan Crane, Karen Bernards, Brian Nelson, Katie Snead, Alison Angione, Amber Sherman, Shawn DeVault, Jim Hnilo, jameel Shah. Long term cell culture models to identify biomarkers of response. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4259.